Hepatic Disease in HIV-Infected Patients
Summary
- In randomized, controlled trials, the proportion of patients receiving combination ART who have grades 3 or 4 elevations in serum ALT or AST levels range from approximately 2% to 18%[Nuñez 2006]
- Ritonavir-boosted PIs have not been associated with higher rates of hepatotoxicity
- Liver enzyme elevations in large registration studies were infrequently symptomatic or dose limiting, and permanent liver injury was a distinctly rare event
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content